SSY Group Full Year 2024 Earnings: Misses Expectations

SSY Group (HKG:2005) Full Year 2024 Results

Key Financial Results

• Revenue: HK$5.77b (down 11% from FY 2023).
• Net income: HK$1.06b (down 20% from FY 2023).
• Profit margin: 18% (down from 20% in FY 2023). The decrease in margin was driven by lower revenue.
• EPS: HK$0.36 (down from HK$0.44 in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

2005 Post-Clinical Trial Products

• Approved (during full year): 119.

All figures shown in the chart above are for the trailing 12 month (TTM) period

SSY Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 5.7% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for SSY Group that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.